Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century

Ziniu Tang, Chen Wang, Zhenyu Ma, Peng Shang, Qipeng Yuan, Jinbo YueJournal of Cancer Research and Clinical Oncology 2025 · DOI

Abstract

T-cell immunotherapy for pancreatic cancer (PC) is a rapidly advancing, interdisciplinary domain led by the United States with rising contributions from China. Accelerating clinical translation will require: integrated T-cell engineering with microenvironment remodeling; rational combinations with checkpoint and stroma-targeted agents; robust predictive biomarkers with standardized endpoints; safety-engineering and risk-mitigation frameworks; and coordinated, multicenter collaboration. This bibliometric synthesis delineates the field's structure and priorities to improve outcomes for patients with PC.

Introduction

This bibliometric study, published in the Journal of Cancer Research and Clinical Oncology, provides a high-level "map" of the research landscape for T-cell immunotherapy in pancreatic cancer from 2000 to 2024. By analyzing over two decades of scholarly data, the authors identify key players, shifting research priorities, and emerging technologies—such as AI and cellular engineering—that are defining the next generation of cancer treatment.

Pancreatic cancer remains one of the deadliest malignancies, largely because it is immunologically "cold." Unlike "hot" tumors teeming with immune cells, PC is characterized by a low mutational burden and a dense, "desmoplastic" stroma—a physical and chemical fortress that excludes T cells. This study clarifies which institutions are leading the charge and which thematic "hotspots" are most likely to yield clinical breakthroughs.

Methodology and Data Overview

The researchers employed a systematic bibliometric approach, utilizing metadata for 527 articles and reviews extracted from the Web of Science Core Collection (WOSCC). Analysis was performed using VOSviewer for science-mapping, CiteSpace for detecting citation bursts, and the R "bibliometrix" package for descriptive statistics.

Summary statistics of the bibliometric dataset, highlighting the scale of research from 2000 to 2024.

The primary dataset encompasses 229 sources and nearly 4,000 authors, reflecting a broad international effort to tackle the complexities of PC immunotherapy.

Research activity in this field experienced a significant inflection point in 2017. Since then, publication volume has surged, with the last three years each contributing over 50 publications. This reflects a global shift toward addressing the challenges of "cold" tumors.

Annual and cumulative publication output alongside average citations per year, illustrating the field's rapid expansion and impact.

Key results from the impact analysis include:

  • Growth: A peak annual growth rate of 41.1%.
  • Impact: An average of 5.99 citations per publication per year, with a notable peak in 2021 (15.75 citations per publication).
  • Geopolitical Leadership: The USA leads in academic influence (183 publications), while China is rapidly closing the gap in volume (137 publications). Germany remains a dominant European hub, led by the Helmholtz Association.

Thematic Evolution: From Vaccines to Precision Engineering

The field has undergone a dramatic thematic shift. Early research in the 2000s focused on broad concepts like vaccination and dendritic cells. Today, the frontier has moved toward high-precision interventions:

  • CAR-T and TCR Engineering: Developing chimeric antigen receptor and T-cell receptor technologies tailored for solid tumors.
  • TME Remodeling: Strategies to penetrate and modulate the suppressive tumor microenvironment.
  • AI-Enabled Discovery: Utilizing artificial intelligence for target discovery and biomarker-guided patient stratification.

Future Frontiers and Limitations

While the study provides a comprehensive overview, it is limited by its reliance on a single database (WOSCC) and the inherent citation lag that may under-represent the most recent breakthroughs.

Moving forward, the authors emphasize three critical areas for the next generation of research: integrated engineering to break down the pancreatic stroma, precision medicine using liquid biopsies and neoantigen targeting, and the development of robust safety frameworks to mitigate off-target toxicities in CAR-T therapies. This coordinated, multicenter approach is essential for translating these bibliometric "hotspots" into improved clinical outcomes for patients with pancreatic cancer.

Summary updated

Abstract

T-cell immunotherapy for PC is a rapidly advancing, interdisciplinary domain led by the United States with rising contributions from China. Accelerating clinical translation will require: integrated T-cell engineering with microenvironment remodeling; rational combinations with checkpoint and stroma-targeted agents; robust predictive biomarkers with standardized endpoints; safety-engineering and risk-mitigation frameworks; and coordinated, multicenter collaboration. This bibliometric synthesis delineates the field's structure and priorities to improve outcomes for patients with PC.
BibTeX
@article{tang2025mapping,
  author = {Ziniu Tang and Chen Wang and Zhenyu Ma and Peng Shang and Qipeng Yuan and Jinbo Yue},
  title = {{Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century}},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06356-x},
}
Figure